Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Karuna Therapeutics Inc (KRTX)
Karuna Therapeutics Inc (KRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,063,920
  • Shares Outstanding, K 38,148
  • Annual Sales, $ 650 K
  • Annual Income, $ -433,680 K
  • 60-Month Beta 1.18
  • Price/Sales 18,313.96
  • Price/Cash Flow N/A
  • Price/Book 9.44
Trade KRTX with:

Options Overview Details

View History
  • Implied Volatility 19.60% ( -2.02%)
  • Historical Volatility 7.28%
  • IV Percentile 16%
  • IV Rank 19.35%
  • IV High 69.93% on 10/13/23
  • IV Low 7.53% on 01/17/24
  • Put/Call Vol Ratio 0.74
  • Today's Volume 68
  • Volume Avg (30-Day) 852
  • Put/Call OI Ratio 1.75
  • Today's Open Interest 25,449
  • Open Int (30-Day) 24,038

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.99
  • Number of Estimates 7
  • High Estimate -2.50
  • Low Estimate -3.22
  • Prior Year -2.80
  • Growth Rate Est. (year over year) -6.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
296.06 +7.34%
on 02/26/24
321.45 -1.13%
on 02/15/24
+2.92 (+0.93%)
since 02/02/24
3-Month
190.01 +67.26%
on 12/07/23
321.45 -1.13%
on 02/15/24
+120.23 (+60.86%)
since 12/04/23
52-Week
158.38 +100.67%
on 10/03/23
321.45 -1.13%
on 02/15/24
+122.30 (+62.56%)
since 03/03/23

Most Recent Stories

More News
GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s...

BIIB : 220.98 (+0.01%)
GILD : 72.24 (-0.10%)
KRTX : 317.63 (+0.44%)
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

ADAP : 1.5225 (-4.25%)
SPRO : 1.6800 (-0.59%)
KRTX : 317.63 (+0.44%)
LSTA : 3.15 (+1.61%)
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 317.63 (+0.44%)
Karuna Therapeutics to Present at Upcoming Investor Conferences

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 317.63 (+0.44%)
3 Biotech Buyout Targets to Watch

The trio all have late-stage therapies with blockbuster potential.

ETNB : 14.07 (+11.49%)
KRTX : 317.63 (+0.44%)
MORF : 37.72 (-4.58%)
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 25.46 (-4.75%)
PRTC.LN : 198.400 (-1.78%)
BIIB : 220.98 (+0.01%)
KRTX : 317.63 (+0.44%)
VOR : 2.32 (+2.20%)
AKLI : 0.3335 (-4.71%)
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 317.63 (+0.44%)
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological...

KRTX : 317.63 (+0.44%)
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

BIIB : 220.98 (+0.01%)
GILD : 72.24 (-0.10%)
INCY : 59.10 (+0.08%)
ALT : 11.24 (-7.03%)
KRTX : 317.63 (+0.44%)
Karuna Therapeutics to Present at the Stifel 2023 CNS Days

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 317.63 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's product candidate consists of KarXT, for the treatment of acute...

See More

Key Turning Points

3rd Resistance Point 320.09
2nd Resistance Point 318.55
1st Resistance Point 317.39
Last Price 317.63
1st Support Level 314.69
2nd Support Level 313.15
3rd Support Level 311.99

See More

52-Week High 321.45
Last Price 317.63
Fibonacci 61.8% 259.16
Fibonacci 50% 239.91
Fibonacci 38.2% 220.67
52-Week Low 158.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar